Cargando…

CTLA-4 promotes lymphoma progression through tumor stem cell enrichment and immunosuppression

The recurrence rate of lymphoma is very high, and tumor stem cells may be an important mechanism. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can inhibit antitumor immunity and promote cancer progression, but its role and mechanism in lymphoma are still unclear. Here we collected lymphoma t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yan, Li, Meng, Cao, Jian, Cai, Guohong, Li, Xiantao, Liu, Yuejiao, Chen, Wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422981/ https://www.ncbi.nlm.nih.gov/pubmed/34553071 http://dx.doi.org/10.1515/biol-2021-0094

Ejemplares similares

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity
por: Watanabe, Tomofumi, et al.
Publicado: (2023)

CTLA4-Mediated Immunosuppression in Glioblastoma is Associated with the Infiltration of Macrophages in the Tumor Microenvironment
por: Guan, Xiudong, et al.
Publicado: (2021)

CTLA4-Ig immunosuppressive activity at the level of dendritic cell/T cell crosstalk
por: Mayer, Edda, et al.
Publicado: (2013)

Immunomodulatory effects of selenium‐enriched peptides from soybean in cyclophosphamide‐induced immunosuppressed mice
por: Zhang, Jian, et al.
Publicado: (2021)

The polysaccharide of Atractylodes macrocephala koidz (PAMK) alleviates cyclophosphamide-mediated immunosuppression in geese, possibly through novel_mir2 targeting of CTLA4 to upregulate the TCR-NFAT pathway
por: Li, Wanyan, et al.
Publicado: (2018)

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
por: Fietz, Simon, et al.
Publicado: (2020)

NLRP7 Promotes Choriocarcinoma Growth and Progression through the Establishment of an Immunosuppressive Microenvironment
por: Reynaud, Deborah, et al.
Publicado: (2021)

Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance
por: Rodriguez, B. Leticia, et al.
Publicado: (2023)

Immunosuppressive lncRNA LINC00624 promotes tumor progression and therapy resistance through ADAR1 stabilization
por: Zhang, Qi, et al.
Publicado: (2022)

Confusing signals: Recent progress in CTLA-4 biology
por: Walker, Lucy S.K., et al.
Publicado: (2015)

Stress-induced immunosuppression affecting immune response to Newcastle disease virus vaccine through “miR-155-CTLA-4” pathway in chickens
por: Wen, Jie, et al.
Publicado: (2023)

Recent research and clinical progress of CTLA-4-based immunotherapy for breast cancer
por: Zhang, Hongsheng, et al.
Publicado: (2023)

Transcriptome and single-cell analysis reveal the contribution of immunosuppressive microenvironment for promoting glioblastoma progression
por: Ni, Lulu, et al.
Publicado: (2023)

Group‐2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2‐Neutrophil‐Induced Immunosuppression
por: Xu, Xingyuan, et al.
Publicado: (2021)

CTLA-4 Insufficiency due to a Novel CTLA-4 Deletion, Identified through Copy Number Variation Analysis
por: Olfe, Lisa, et al.
Publicado: (2022)

Interleukin-17 enhances immunosuppression by mesenchymal stem cells
por: Han, X, et al.
Publicado: (2014)

SHMT2 regulates serine metabolism to promote the progression and immunosuppression of papillary renal cell carcinoma
por: Kong, Weiyu, et al.
Publicado: (2022)

Analysis of single nucleotide polymorphisms in the FAS and CTLA-4 genes of peripheral T-cell lymphomas
por: Bonzheim, Irina, et al.
Publicado: (2008)

Polymorphisms in the CTLA4 promoter sequence are associated with canine hypoadrenocorticism
por: Boag, Alisdair M., et al.
Publicado: (2020)

USP22 promotes development of lung adenocarcinoma through ubiquitination and immunosuppression
por: Han, Bing, et al.
Publicado: (2020)

CTLA-4 Expression Plays a Role in PSC and PBC Progression
por: Meister, Phil, et al.
Publicado: (2020)

Dysregulated Expression of Both the Costimulatory CD28 and Inhibitory CTLA-4 Molecules in PB T Cells of Advanced Cervical Cancer Patients Suggests Systemic Immunosuppression Related to Disease Progression
por: Kosmaczewska, Agata, et al.
Publicado: (2011)

Ischemia–Reperfusion Injury and Immunosuppressants Promote Polyomavirus Replication Through Common Molecular Mechanisms
por: Chen, Xu-Tao, et al.
Publicado: (2022)

CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal Cells
por: Gaber, Timo, et al.
Publicado: (2018)

Osthole enhances the immunosuppressive effects of bone marrow‐derived mesenchymal stem cells by promoting the Fas/FasL system
por: Yu, Yang, et al.
Publicado: (2021)

Analysis of Lymphoma-Related Genes with Gene Ontology and Kyoto Encyclopedia of Genes and Genomes Enrichment
por: Sun, Qiao, et al.
Publicado: (2022)

Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma
por: Ye, Shu-biao, et al.
Publicado: (2014)

Exosomal PD‑L1 promotes the formation of an immunosuppressive microenvironment in gastric diffuse large B‑cell lymphoma
por: Zeng, Hui, et al.
Publicado: (2023)

LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade
por: Hickman, Amber, et al.
Publicado: (2022)

Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells
por: Clavijo, Paul E., et al.
Publicado: (2017)

Mesenchymal stromal cells promote B-cell lymphoma in lacrimal glands by inducing immunosuppressive microenvironment
por: Lee, Min Joung, et al.
Publicado: (2017)

HGF/c-Met Promote Renal Carcinoma Cancer Stem Cells Enrichment Through Upregulation of Cir-CCDC66
por: Yang, Juhong, et al.
Publicado: (2020)

The S100A8/A9 complex reduces CTLA4 expression by immature myeloid cells: Implications for pancreatic cancer-driven immunosuppression
por: Basso, Daniela, et al.
Publicado: (2013)

Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression
por: Pavicic, Paul G., et al.
Publicado: (2023)

NAT10/ac4C/FOXP1 Promotes Malignant Progression and Facilitates Immunosuppression by Reprogramming Glycolytic Metabolism in Cervical Cancer
por: Chen, Xiaona, et al.
Publicado: (2023)

Commentary on “CTLA-4 Blockade Suppresses Progression of Residual Tumours after Insufficient RFA”
por: Geboers, B., et al.
Publicado: (2020)

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2021)

Mesenchymal stem cells alleviate experimental autoimmune cholangitis through immunosuppression and cytoprotective function mediated by galectin-9
por: Fan, Junyu, et al.
Publicado: (2018)

Abatacept is effective in Chinese patients with LRBA and CTLA4 deficiency
por: Yang, Lu, et al.
Publicado: (2020)

Activation of mesenchymal stem cells by macrophages promotes tumor progression through immune suppressive effects
por: Jia, Xiao-hua, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_934cd7a8v60lb43vijn0t05m1v